Trial reportGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2023
Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study.
Trial report in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Radiation Therapy for Gastric Cancer: An ASTRO Clinical Practice Guideline.Practical radiation oncologyGuideline
- Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Trial
- Perioperative Chemoimmunotherapy for Resectable Gastric and Gastroesophageal Junction Cancer: A Conceptual, Biomarker-Informed, and Regionally Adapted Framework.Journal of gastrointestinal cancer · 2026Review
- Clinical efficacy and safety of apatinib plus S-1 combined with oxaliplatin (SOX) in postoperative stage III gastric cancer patients with high VEGFR-2 expression.Journal of gastrointestinal oncology · 2026Article
- Comparative Effectiveness of Adjuvant XELOX Versus TS-1 Monotherapy After D2 Gastrectomy for Stage III Gastric Cancer: A Real-World Nationwide Cohort Study.Life (Basel, Switzerland) · 2026Article
- High PD-L1 expression as a negative prognostic factor in stage III but not in stage II gastric cancer.World journal of gastroenterology · 2026Article
- Neoadjuvant Chemotherapy for Gastric Cancer: Evolving Approaches and Supporting Evidence.Journal of gastric cancer · 2026Review
- Impact of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel delivery on postoperative survival in locally advanced oesophagogastric adenocarcinoma.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Article
- Efficacy and Safety of a 3-Weekly TS-1 Adjuvant Regimen in Advanced Gastric Cancer: A Pilot Study.Cancer medicine · 2025Article
- Long-term outcomes of S-1 monotherapy in stage IIIA gastric cancer with small tumors and low nodal involvement.Langenbeck's archives of surgery · 2025Article
- Successful robot-assisted minimally invasive surgery for scirrhous gastric conduit cancer after esophagectomy: A case report.Oncology letters · 2025Article
- Postoperative adjuvant chemotherapy in patients with gastric cancer based on the Nationwide Gastric Cancer Registry in Japan.Global health & medicine · 2025Article
- Predictors of tolerability for postoperative adjuvant S1 plus docetaxel chemotherapy for gastric cancer: a multicenter retrospective study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Article
- Camrelizumab plus SOX chemotherapy as adjuvant therapy for pathological stage III gastric or gastroesophageal junction adenocarcinoma: a prospective, multicenter, single-arm, phase II trial.Therapeutic advances in medical oncology · 2025Article
- Enhancing Preoperative Diagnosis Accuracy of Stage III Gastric Cancer with Circulating circRNAs.Annals of surgical oncology · 2025Article
- Article
- Efficacy of chemotherapy for patients with gastric cancer with early recurrence during or after adjuvant chemotherapy with S-1 alone: a multicenter retrospective study.Scientific reports · 2024Article
- Adjuvant treatment for locally advanced gastric cancer: an Asian perspective.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Review
- Pan-caner analysis identifies PSMA7 as a targets for amplification at 20q13.33 in tumorigenesis.Scientific reports · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA phase III trial comparing S-1 and docetaxel with S-1 alone as postoperative chemotherapy for pathologically Stage III gastric cancer was conducted and clarified the superiority of the doublet in terms of 3-year relapse-free survival as the primary endpoint (67.7% versus 57.4%, hazard ratio [HR] 0.715, 95% confidence interval [CI] 0.587-0.871; p = 0.0008). This final report analyzed 5-year survival outcomes along with the incidence and pattern of late recurrences. PATIENTS AND
methodsPatients with histologically confirmed Stage III gastric cancer who underwent gastrectomy with D2 lymphadenectomy were randomly assigned to receive adjuvant chemotherapy with either S-1 plus docetaxel or S-1 alone. The same 912 patients who were evaluated for 3-year survival outcomes in the previous report were analyzed.
resultsFive-year overall survival rate of the S-1 plus docetaxel group (67.91%) was significantly superior to that in the S-1 group (60.27%; HR 0.752, 95% CI 0.613-0.922; p = 0.0059). The incidence of late recurrence at > 3 years after randomization was similar in both groups (7.3% versus 7.2%). Peritoneal dissemination was the most common pattern of late recurrence. Addition of docetaxel significantly suppressed relapse through the lymphatic (6.8% [95% CI 4.52-9.17] versus 15% [95% CI 11.76-18.30]; p < 0.0001) and hematogenous (10.2% [95% CI 7.37-12.94] versus 15.7% [95% CI 12.36-19.01]; p < 0.0137) pathways throughout the 5 years of follow-up.
conclusionThe survival benefit of postoperative chemotherapy with S-1 and docetaxel in terms of 5-year overall survival rate was confirmed for patients with pathologically Stage III gastric cancer, although late recurrences were not prevented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.